Abbott Laboratories (ABT) concluded trading on Wednesday at a closing price of $112.90, with 3.55 million shares of worth about $400.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -5.96% during that period and on August 28, 2024 the price saw a loss of about -0.18%. Currently the company’s common shares owned by public are about 1.73B shares, out of which, 1.73B shares are available for trading.
However, the stock later moved at a day high price of 113.42, or with a loss of -0.18%. Stock saw a price change of 1.36% in past 5 days and over the past one month there was a price change of 7.20%. Year-to-date (YTD), ABT shares are showing a performance of 2.57% which increased to 9.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $89.67 but also hit the highest price of $121.64 during that period. The average intraday trading volume for Abbott Laboratories shares is 6.42 million. The stock is currently trading 2.34% above its 20-day simple moving average (SMA20), while that difference is up 5.97% for SMA50 and it goes to 4.06% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Abbott Laboratories (NYSE: ABT) currently have 1.73B outstanding shares and institutions hold larger chunk of about 79.82% of that.
The stock has a current market capitalization of $196.43B and its 3Y-monthly beta is at 0.72. PE ratio of stock for trailing 12 months is 35.63, while it has posted earnings per share of $3.17 in the same period. Its PEG reads 4.35 and has Quick Ratio of 1.18 while making debt-to-equity ratio of 0.38. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABT, volatility over the week remained 0.94% while standing at 1.75% over the month.
Stock’s fiscal year EPS is expected to rise by 4.96% while it is estimated to increase by 10.36% in next year. EPS is likely to shrink at an annualized rate of 8.20% for next 5-years, compared to annual growth of 19.65% made by the stock over the past 5-years.
Coverage by Goldman stated Abbott Laboratories (ABT) stock as a Buy in their note to investors on May 30, 2024, suggesting a price target of $121 for the stock. On July 21, 2023, Wolfe Research Upgrade their recommendations, while on May 30, 2023, Morgan Stanley Downgrade their ratings for the stock with a price target of $112. Stock get an Underperform rating from Wolfe Research on April 20, 2023.
